Research programme: dihydroorotate dehydrogenase inhibitors - Chelsea Therapeutics

Drug Profile

Research programme: dihydroorotate dehydrogenase inhibitors - Chelsea Therapeutics

Alternative Names: DHODH inhibitors - Chelsea Therapeutics; I-3D project

Latest Information Update: 27 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Active Biotech
  • Developer Lundbeck A/S
  • Class Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Autoimmune disorders; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 24 Jun 2014 Chelsea Therapeutics has been acquired and merged into Lundbeck A/S
  • 08 Apr 2008 Chelsea Therapeutics International acquires global rights to I-3D from Active Biotech
  • 02 Nov 2006 Preclinical trials in Rheumatoid arthritis in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top